BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/16/2023 9:24:22 AM | Browse: 302 | Download: 1374
 |
Received |
|
2022-12-04 14:05 |
|
Peer-Review Started |
|
2022-12-04 14:07 |
|
First Decision by Editorial Office Director |
|
2023-02-07 09:04 |
|
Return for Revision |
|
2023-02-07 09:04 |
|
Revised |
|
2023-02-17 18:08 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2023-04-06 03:10 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2023-04-06 07:57 |
|
Articles in Press |
|
2023-04-06 07:57 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-04-25 07:43 |
|
Publish the Manuscript Online |
|
2023-05-16 09:24 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Case Report |
| Article Title |
Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn’s disease: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Mei-Juan Gao, Yan Xu and Wen-Bo Wang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mei-Juan Gao, MD, Chief Physician, Department of Endocrinology, Peking University Shougang Hospital, No. 9, Jinyuanzhuang Road, Beijing 100041, China. gmjluhe@163.com |
| Key Words |
Immune checkpoint inhibitor; Programmed cell death protein 1 ligand; Autoimmune polyendocrine syndrome type II; Type 1 diabetes mellitus; Thyroiditis; Crohn’s disease; Case report |
| Core Tip |
We report a rare case of multi-system damage induced by cancer therapy with protein 1 ligand inhibitor teriprizumab. A man with squamous cell carcinoma of oropharynx on a combination regimen of teriprizumab, docetaxel, and cisplatin developed autoimmune polyendocrine syndrome type II (APS-2) including thyroiditis and type 1 diabetes mellitus (T1DM) and Crohn’s disease (CD). This case report highlights the possibility of chronic immune toxicities and the long-term implications of cancer immunotherapy. To the best of our knowledge, this is the first reported case of concurrent atypical APS-2 (including T1DM and thyrotoxicosis) and CD in a patient receiving immunotherapy for metastatic nasopharyngeal carcinoma. |
| Publish Date |
2023-05-16 09:24 |
| Citation |
Gao MJ, Xu Y, Wang WB. Immune checkpoint inhibitor therapy-induced autoimmune polyendocrine syndrome type II and Crohn’s disease: A case report. World J Clin Cases 2023; 11(14): 3267-3274 |
| URL |
https://www.wjgnet.com/2307-8960/full/v11/i14/3267.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v11.i14.3267 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
